Table 1 Subject demographics (all primary cohort subjects)
N = 1000 Subjects | |
|---|---|
Age at consent (years) | 67.7 ± 11.3 (1000) [69.0] (21.0–93.0) |
Female/Male | 49.1%/50.9% |
Race | |
White | 85.5% (855/1000) |
Black or African American | 12.5% (125/1000) |
Asian | 0.6% (6/1000) |
American Indian or Alaska Native | 0.4% (4/1000) |
Native Hawaiian or Other Pacific Islander | 0.1% (1/1000) |
Unknown | 0.8% (8/1000) |
Unable To Report | 0.1% (1/1000) |
Hispanic or Latino Ethnicity | 4.4% (44/1000) |
Tobacco History (Current or Former) | 80.8% (807/999) |
COPD | 44.8% (448/999) |
FEV1 (% of predicted) | 74.8 ± 25.6 (332) [75.5] (20.0–140.0) |
FEV1/FVC Ratio | 0.9 ± 0.2 (331) [0.9] (0.3–1.9) |
DLCO (% of predicted) | 66.4 ± 24.9 (225) [66.0] (6.0–141.0) |
Asthma | 12.6% (126/999) |
Prior Invasive Lung Proceduresa | 30.6% (306/1000) |
Bronchoscopy | 20.4% (204/1000) |
Standard Bronchoscopy | 12.3% (123/1000) |
Image-guided Bronchoscopyb | 9.7% (97/1000) |
Transthoracic Needle Aspiration | 5.1% (51/1000) |
Surgery | 11.1% (111/1000) |
Other | 3.0% (30/1000) |
Personal History of Cancer | 45.8% (458/999) |
Family History of Cancer | 61.3% (612/999) |
Subject taking Antithrombotic Medicationsc | 45.8% (458/1000) |
Anticoagulant | 10.2% (102/1000) |
Prescription Antiplatelet | 6.8% (68/1000) |
Aspirin | 32.5% (325/1000) |
Other | 1.4% (14/1000) |